Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-46 (Canceled)

47. (Currently Amended) A bispecific antibody, or a binding fragment thereof, comprising a first determinant that binds to an Immunoreceptor Tyrosine-Based Activation Module (ITAM), wherein said ITAM is selected from the group consisting ~~consisiting~~ of BCR, FcεRI, FcγRI, FcγRIIA, FcγRIIIA, and TCR, and a second determinant that binds to an Immunoreceptor Tyrosine-Based Inhibition Module (ITIM), wherein said ITIM is selected from the group consisting ~~consisiting~~ of FcγRIIB, ~~FcγRIII~~, and FcεRII.

48. (Previously Presented) The bispecific antibody of claim 47 or a binding fragment thereof, comprising antigen-binding regions from two different antibodies.

49. (Previously Presented) The bispecific antibody of claim 47, wherein the ITIM is FcεRII.

50. (Currently Amended) The bispecific antibody of claim 47, wherein the ITIM is FcγRIIB.

51. (Previously Presented) A composition comprising the bispecific antibody of claim 47, or a binding fragment thereof, and a physiologically acceptable carrier, excipient, or diluent.

52. (Previously Presented) The bispecific antibody of claim 47, wherein at least one determinant is humanized, human, chimeric, or an ScFv.

53. (Currently Amended) A method of inhibiting the release of TNF-α from a mast cell or a basophil comprising administering a [[the]] bispecific antibody ~~of claim 47~~, or a binding fragment thereof comprising a first determinant that binds to an Immunoreceptor Tyrosine-Based Activation Module (ITAM), wherein said ITAM is selected from the group consisting of FcεRI, FcγRI, FcγRIIA, and FcγRIIIA, and a second determinant that binds to an Immunoreceptor Tyrosine-Based Inhibition Module (ITIM), wherein said ITIM is FcγRIIB or FcεRII.

54. (Currently Amended) A method of inhibiting the release of histamine from a mast cell or a basophil comprising administering a [[the]] bispecific antibody ~~of claim 47~~, or a binding fragment thereof comprising a first determinant that binds to an Immunoreceptor Tyrosine-Based Activation Module (ITAM), wherein said ITAM is selected from the group consisting of FcεRI, FcγRI, FcγRIIA, and FcγRIIIA, and a second determinant that binds to an Immunoreceptor Tyrosine-Based Inhibition Module (ITIM), wherein said ITIM is FcγRIIB or FcεRII.

55. (Currently amended) The method of claim 53, wherein the bispecific antibody is administered at a concentration range[[s]] from 0.1 to 1 μg/ml.

56. (Previously Presented) A method of ameliorating an allergic disease or condition in a mammal comprising administering the bispecific antibody of claim 47, or a binding fragment thereof.